DOCS — DOXIMITY INC.

Doximity is the only verified professional network reaching more than 85% of U.S. physicians, generating $267 million in free cash flow last year at 90% gross margins with net revenue retention of 112% — the financial signature of a platform its customers cannot afford to leave. The stock has fallen 61% in twelve months as federal drug pricing policy created uncertainty that caused pharmaceutical customers to defer annual budget commitments rather than cancel them. At an enterprise value of $3.65 billion — under 14 times last year's free cash flow — the market is pricing in permanent stagnation for a near-monopoly platform whose AI monetization layer is already in 300,000 physicians' daily workflows and has not generated a single dollar of booked revenue.

---

Drug pricing is the central anxiety in American healthcare in early 2026. The Inflation Reduction Act's Medicare negotiation mechanism has been grinding through the system since 2024, and in December of last year sixteen of the largest pharmaceutical companies signed Most Favored Nation pricing agreements that created sudden uncertainty about the economics of their most important products. When a company that sells a $60,000-per-year biologic learns in December that its pricing structure may be renegotiated against international benchmarks, its marketing department does not immediately know whether the product's commercial logic has changed. The rational response — pause, defer, wait for the picture to clarify — is exactly what happened to Doximity's Q4 fiscal 2026 guidance. Management described customers who "deployed a lower percentage of their annual budgets upfront than historical norms." Not customers who canceled. Not customers who left. Customers who were slow to commit while an external shock was absorbed.

This distinction — deferred versus canceled, timing versus structural — is the entire analytical question for a potential investor in Doximity today. The stock has been repriced as if the answer is structural. The evidence in the business metrics suggests the answer is timing. At the current valuation, the stakes of getting this question right are significant in both directions.

The digital health sector has spent the past two years in a de-rating cycle that has compressed multiples across the category. Companies that went public in 2021 at triple-digit earnings multiples have, nearly without exception, faced the correction that comes when growth assumptions prove optimistic or when rate environments change the discount applied to future earnings. Doximity's multiple has compressed from above 80 times earnings in fiscal 2022 to roughly 20 times trailing earnings today. In a market that has been burned by healthcare SaaS disappointments, the tendency is to conflate valuation compression with business deterioration. They are not the same thing here.

Pharmaceutical companies spend approximately $31 billion per year on marketing in the United States. The majority of that historically flowed to field sales representatives — the army of detail reps who called on physician offices with samples and product literature. That model has been in structural decline for a decade: physician access restrictions have tightened as large health systems implement no-rep policies, practice consolidation has reduced the number of independent prescribers who control their own formulary decisions, and the economics of maintaining a large field force have deteriorated as products become more complex and specialist-targeted. The budget that used to flow to reps has to go somewhere. It has been going to digital HCP marketing, and the shift is not complete.

What makes the HCP digital advertising market structurally different from consumer digital advertising is the targeting problem. A pharmaceutical company launching a treatment for a rare autoimmune condition needs to reach approximately four thousand rheumatologists and immunologists in the United States — not four hundred million general internet users. The precision required is extreme. The clinical context matters: an advertisement seen by a specialist who has just logged off a patient consultation for the relevant condition is worth an order of magnitude more than a banner seen during casual browsing. And the audience must be verified — the FDA does not take kindly to promotional materials reaching non-prescribers, and health system compliance requirements have made HIPAA-compliant delivery a requirement rather than a preference. A platform that can deliver verified specialty segmentation, behavioral targeting by prescribing patterns, and HIPAA-compliant delivery in a contextually relevant clinical environment holds structural pricing power that no general-purpose digital channel can match.

The total U.S. healthcare and pharma digital advertising market reached approximately $24.8 billion in 2025, growing at 13% annually as budgets continue migrating from linear channels. The endemic physician-specific slice — platforms where physicians show up explicitly for professional purposes — is a fraction of that total but captures the highest CPMs available in digital advertising because the targeting precision and clinical context are irreproducible in general channels. Doximity's $570 million in fiscal 2025 revenue represents a meaningful but still relatively small share of the addressable premium HCP marketing market, implying substantial room to grow the revenue base even without expansion into entirely new product categories.

Doximity was founded in 2010 by Jeff Tangney, who had previously co-founded Epocrates in 1998 — a drug reference tool for Palm Pilots that grew to approximately $100 million in revenue before being acquired by Athenahealth for $293 million in 2009. Tangney's thesis for Doximity was specific: physicians, like every other professional cohort, would eventually want a verified online network for communication, career management, and clinical collaboration, and the network's verified identity layer — built against the federal National Provider Identifier registry — would become enormously valuable to any enterprise needing to reach physicians with precision. The company spent its first decade building physician audience through clinical utility tools before layering marketing solutions on top. By the time it went public in 2021 it had assembled a network that more than 80% of U.S. physicians had voluntarily joined, making it the single most effective channel for verified physician-targeted digital marketing ever assembled.

The business model has an elegant structure that is easy to describe but difficult to replicate. Physicians use the platform at no charge and receive continuous value: a telehealth dialer that lets them call patients without revealing their personal phone number, an AI scribe that generates structured clinical notes from ambient conversation, a clinical reference tool answering drug interaction and treatment questions with peer-reviewed citations, HIPAA-compliant secure messaging, electronic fax, and a professional newsfeed that functions as a career management and continuing education layer. This physician-side utility drives daily active engagement with no incremental cost to the company and no subscription revenue from doctors. Pharmaceutical companies, health systems, and medical recruiting firms then pay annual enterprise subscription fees for access to that verified, engaged audience. Roughly 95% of revenue is subscription-based, giving the business revenue predictability well above what advertising-dependent models typically achieve.

The moat argument begins with a number: more than 85% of the approximately 1.1 million active U.S. physicians are verified members of Doximity. That is not a plurality. It is near-total capture of the professional population that pharmaceutical companies need most urgently to reach. A competing platform seeking to challenge this position would need to persuade the same physicians to join a new network, complete a new verification process, integrate new workflow tools into their daily clinical routine, and do so while Doximity continues adding features and deepening its relationship with every major pharmaceutical company, hospital system, and medical recruiting firm in the country. The cost of that migration — in physician time, habit disruption, and competitive inertia — is the structural barrier that explains why no serious competitor has managed to erode Doximity's dominance despite a decade of opportunity.

The network effect has three layers that compound on each other. The first is the physician-to-physician layer: a verified professional graph where colleagues can identify each other by specialty and institution, send HIPAA-compliant messages, and collaborate clinically. The value of this graph scales with its completeness; at 85% physician penetration, looking up a colleague and finding them on Doximity is essentially certain. The second layer is the physician-to-pharma advertising channel, where the same verified network physicians joined for communication becomes the captive audience for pharmaceutical marketing. The third layer is workflow embeddedness: physicians who use Doximity's fax, dialer, AI scribe, and clinical reference tools daily are not evaluating the platform's social features each morning — they are operating their practice through it. The 720,000 quarterly active prescribers using workflow tools as of the most recent quarter is not a number that emerges from passive engagement; it represents physicians who have integrated the platform into clinical routines that would need to be rebuilt from scratch to leave.

The financial signature of this moat is net revenue retention. At 112% overall and 117% for the top twenty customers in the most recent quarter, Doximity's enterprise clients are spending more on the platform year-over-year even during a period of external budget uncertainty. This is the mathematical equivalent of customers who understand the platform well, who have alternatives, who have budget authority to reallocate — choosing to spend more, not less. The step-down from 119% at fiscal 2025 year-end to 112% in the most recent quarter reflects the MFN-driven deceleration, not a structural shift in willingness to pay. The top-twenty NRR holding at 117% — the cohort that knows Doximity best and has the most leverage to renegotiate — is the more diagnostic number.

Platform	Verified U.S. Physician Reach	HIPAA Workflow Tools	Pharma Targeting Precision
Doximity	85%+ of all U.S. MDs (~935,000)	Full suite — telehealth, fax, AI scribe, messaging	NPI-level, specialty, geographic, behavioral
Sermo	~400–500K globally; U.S.-only count smaller, anonymous	None	Survey-based market research only
Medscape / WebMD	Large readership; no credential verification	None	Cookie/contextual; no NPI targeting
Epocrates	Drug reference tool; not a network	None	Not a marketing channel

Doximity has grown revenue from $206.9 million in fiscal 2021 to $570.4 million in fiscal 2025, a four-year compound annual growth rate of approximately 29%. Gross margin has expanded from 84.9% to 90.2% over the same period — an unusual pattern, since most software businesses see margins compress as they scale into less favorable market segments. Doximity's margins improve because adding another pharmaceutical company or health system as a customer requires negligible incremental cost; the physician network and workflow infrastructure are already built. GAAP operating income grew from $53.3 million in fiscal 2021 to $227.8 million in fiscal 2025, representing a 39.9% GAAP operating margin. That is not an adjusted figure with stock compensation and acquisition charges scrubbed out. It is the number produced under standard accounting, before any adjustments.

Free cash flow of $266.7 million in fiscal 2025 represented a 50% increase from the prior year, a 47% FCF margin, and was generated against capital expenditures running below 1% of revenue. The company holds $735 million in cash and marketable securities against zero debt. There is no meaningful reconciliation required between GAAP earnings and cash generation: the business sells annual subscriptions, collects cash upfront, and incurs costs primarily in people and cloud computing. The reported numbers are what the company actually generates. For fiscal 2026, revenue guidance of $642.5 to $643.5 million implies approximately 13% growth over fiscal 2025, and adjusted EBITDA guidance of $355.5 to $356.5 million implies a margin above 55%. The Q4 guidance of $143 to $144 million — just 4% year-over-year — reflects the budget deferral from the MFN uncertainty; the full-year number still represents solid absolute growth despite the compressed quarter.

Jeff Tangney has led Doximity continuously since co-founding it in 2010 — sixteen years in a role he built from nothing. His prior company, Epocrates, sold to Athenahealth for $293 million; his second company went public at a valuation above $9 billion and has returned significant capital to shareholders even from a price 61% below its high. His beneficial ownership at IPO implied a stake valued above $2 billion; he retains approximately 26 to 27% of the company's beneficial economic interest today, meaning his largest financial asset is the same instrument he is asking investors to hold. A CEO whose net worth is primarily denominated in the stock he is asking you to buy is a different kind of principal-agent dynamic than the typical large-cap executive whose compensation is primarily salary and options that vest regardless of long-term returns.

Capital allocation has been disciplined in a way that reflects genuine conviction about intrinsic value. Doximity has made one acquisition of note in its public company history — Pathway Medical in August 2025 for $63 million, a structured medical dataset for clinical decision support integrated into DoxGPT within seven weeks of closing. It is a focused bolt-on, not an empire-building acquisition. Share repurchases have been the primary capital return mechanism: $287.5 million in fiscal 2024, $196.9 million in a single quarter of fiscal 2026, and a new $500 million authorization announced in February 2026 with no expiration date — while the stock sits within percentage points of its all-time post-IPO lows. A management team authorizing and executing large repurchases when the stock is at its cheapest in five years is making a specific statement about where they believe intrinsic value lies relative to price.

Fiscal Year	Revenue ($M)	YoY Growth	NRR	Workflow Users	$500K+ Customers	FCF ($M)
FY2022	$343.6	+66%	—	—	—	$124.7
FY2023	$419.1	+22%	—	—	—	$177.9
FY2024	$475.4	+13%	—	—	99	$184.0
FY2025	$570.4	+20%	119%	620,000	116	$266.7
FY2026E (Q3 data)	~$643	+13%	112%	720,000*	126	est. ~$310

*Record high as of Q3 FY2026; fiscal year ends March 31, 2026. NRR not separately disclosed for FY2022–2024 in available filings.

The table shows a business whose revenue base has nearly doubled in four years while free cash flow has more than doubled and the physician engagement base has reached record levels even as the reported growth rate has decelerated. The NRR step-down from 119% to 112% is the data point most cited by bearish analysts, and it deserves honest assessment: it reflects real near-term pressure from pharma budget timing, and if it continues declining toward 100%, the bull case breaks. But the direction of physician engagement — workflow users at an all-time high of 720,000, with the largest sequential quarterly gain on record — is moving opposite to what a deteriorating competitive position would show. Physicians are using the platform more as the revenue metrics are being temporarily pressured. The two signals together are more informative than either alone.

The penetration argument has two distinct dimensions. On the physician supply side, Doximity has approximately 85% of the 1.1 million active U.S. physicians — the network formation race is essentially over. The relevant penetration story now is on the enterprise demand side: 126 customers generating more than $500,000 in trailing annual subscriptions account for 84% of total revenue, and those 126 accounts are drawn from a universe of pharmaceutical companies, health systems, and medical recruiting firms that numbers well into the thousands. The total addressable enterprise base has barely been touched relative to what the physician network could support. Additionally, the AI monetization layer — 300,000 unique prescribers using AI tools quarterly, 180,000 physicians now covered through hospital system AI purchases, usage rates of four queries per prescriber per week for DoxGPT alone — has generated zero revenue in the current guidance. It is a product cycle sitting in the pipeline that the current price does not reflect.

At the March 28, 2026 closing price of $23.69, Doximity's market capitalization is approximately $4.38 billion. The company holds $735 million in cash and marketable securities against zero debt, implying an enterprise value of roughly $3.65 billion. Against fiscal 2025 free cash flow of $266.7 million, the EV/FCF multiple is approximately 13.7 times. Against trailing twelve-month adjusted EBITDA of approximately $245 million, the EV/EBITDA multiple is approximately 14.9 times. The business has compounded free cash flow at 34% annually over four years, holds gross margins above 90%, has no debt, generates cash at roughly $47 of every $100 in revenue, and is led by a co-founder who has put $500 million of the company's cash into buybacks at the current price. The current multiple is what you would typically pay for a declining legacy business being managed for cash — not a growing near-monopoly network with an unmoneytized AI product layer.

A conservative projection illustrates the valuation gap. If free cash flow grows at 12% annually for five years — below the 34% four-year historical rate, below the current 13% revenue growth rate, assuming zero margin expansion and zero AI monetization — fiscal 2031 free cash flow would be approximately $470 million. At the current enterprise value multiple of 13.7 times, that implies an enterprise value of $6.4 billion, against a current enterprise value of $3.65 billion — approximately 75% upside with no multiple expansion, no AI revenue, and a growth assumption well below historical performance. If the multiple normalizes to 20 times free cash flow, still meaningfully below the 35 to 50 times at which high-quality subscription businesses have historically traded, the implied enterprise value exceeds $9 billion. The math does not require heroic assumptions. It requires only that the business not be structurally broken, which the operating metrics do not suggest it is.

The intelligent bear argues that MFN pricing is secular rather than cyclical — that the political consensus around pharmaceutical pricing is sufficiently durable that pharma marketing budgets will be structurally impaired for years, not quarters, eliminating the re-acceleration thesis. This is the most credible objection. The answer is that pharmaceutical marketing spend has historically tracked to product launch cycles more than to current drug profitability. A company launching a new therapy with a ten-year exclusivity window spends on marketing regardless of what happened to an older product's pricing; the commercial imperative of establishing physician prescribing patterns for a new drug is too important to sacrifice. The near-term pharmaceutical pipeline across Doximity's client base is robust by any measure. And the AI monetization opportunity represents a revenue category entirely disconnected from pharma advertising budgets — a growing enterprise product sold to health systems, not dependent on pharmaceutical commercial cycles at all. The bear's thesis requires both the policy impairment and the AI failure to materialize simultaneously, and currently neither is visible in the operating data.

For the conclusion to change, two specific data points would need to shift: net revenue retention falling below 100% — indicating pharma clients are actively cutting, not just deferring — or quarterly active workflow users peaking and declining, indicating physicians are disengaging from the platform. NRR is currently 112%. Workflow users just reached an all-time high. When the data says one thing and the price implies another, the obligation is to examine which one is wrong. The business operating metrics do not describe a platform whose competitive position is weakening. The price describes a platform that the market has concluded is structurally impaired. One of these is right.

A physician network covering 85% of American doctors, generating free cash flow at 47 cents on every dollar of revenue, led by a founder buying back shares at $23 while sitting on $735 million in cash — and an AI product already in 300,000 clinicians' daily workflows that does not appear in a single dollar of current guidance. The price and the business are not describing the same thing.